Suppr超能文献

度洛西汀治疗颈椎后路手术后轴性症状的临床疗效:一项回顾性研究。

Clinical efficacy of duloxetine in the treatment of axial symptoms after posterior cervical spine surgery: a retrospective study.

机构信息

Department of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, China.

Department of Burn and Plastic Surgery, People's Hospital of Chongqing Hechuan, Chongqing, China.

出版信息

J Orthop Surg Res. 2023 Jul 12;18(1):496. doi: 10.1186/s13018-023-03970-8.

Abstract

PURPOSE

To evaluate the efficacy of duloxetine in the treatment of patients with axial symptoms after posterior cervical spine surgery.

METHODS

Patients with axial symptoms after posterior cervical spine surgery treated by duloxetine or non-drug therapy from 2018 to 2021 were reviewed. Duloxetine was administered gradually, with oral administration of 30 mg in the first week and oral administration of 60 mg from the second week. Visual analogue scale (VAS), 36-Item Short-Form Health Survey questionnaire (SF-36) and EuroQol-5 Dimensions (EQ-5D) questionnaire were used to evaluate the severity of AS at baseline and 1 week, 2 weeks, 1 month, 3 months and 6 months after medication. The occurrence of adverse reactions was recorded.

RESULTS

A total of 63 eligible patients who received duloxetine therapy (n = 35) or non-drug therapy (n = 28) were included. All patients were followed up for 6 months. Significant improvements were found in VAS score compared with baseline in both groups (1.87 ± 0.81 vs 6.61 ± 1.16, 3.18 ± 0.67 vs 6.31 ± 1.40; P < 0.05 for all). Meanwhile, the VAS score of the duloxetine group was significantly better than that of the non-drug therapy group at 1 week, 2 weeks, 1 month, 3 months and 6 months (P < 0.05). Besides, according to 36-Item Short-Form Health Survey questionnaire (SF-36), the PCS score and MCS score are significantly higher than before the treatment in duloxetine group (PCS 62.82 ± 6.04 vs 44.36 ± 7.25, MCS 65.50 ± 4.53 vs 55.55 ± 6.06; P < 0.05 for all). And when we compared variables between the two groups, the PCS score of the duloxetine group was significantly better than that of the non-drug therapy group (P < 0.05), but there was no significant difference in MCS score between the two groups (P > 0.05). What's more, EQ-5D score had significant improvements in the duloxetine group compared with the non-drug therapy group at 1 week, 2 weeks, 1 month, 3 months and 6 months (P < 0.05).

CONCLUSION

Oral duloxetine has a better short-term outcome than conventional non-drug therapy in patients with axial symptoms following posterior decompression surgery in the cervical spine.

摘要

目的

评估度洛西汀治疗颈椎后路手术后轴性症状患者的疗效。

方法

回顾 2018 年至 2021 年接受度洛西汀或非药物治疗的颈椎后路手术后轴性症状患者。度洛西汀逐渐给药,第 1 周口服 30mg,第 2 周起口服 60mg。采用视觉模拟量表(VAS)、36 项简短健康调查量表(SF-36)和欧洲五维健康量表(EQ-5D)问卷在基线和药物治疗后 1 周、2 周、1 个月、3 个月和 6 个月评估 AS 的严重程度。记录不良反应的发生情况。

结果

共纳入 63 例接受度洛西汀治疗(n=35)或非药物治疗(n=28)的合格患者。所有患者均随访 6 个月。两组 VAS 评分均较基线显著降低(1.87±0.81 比 6.61±1.16,3.18±0.67 比 6.31±1.40;均 P<0.05)。同时,度洛西汀组在 1 周、2 周、1 个月、3 个月和 6 个月时 VAS 评分均明显优于非药物治疗组(均 P<0.05)。此外,根据 36 项简短健康调查量表(SF-36),度洛西汀组的躯体成分评分(PCS)和精神成分评分(MCS)均显著高于治疗前(PCS 62.82±6.04 比 44.36±7.25,MCS 65.50±4.53 比 55.55±6.06;均 P<0.05)。两组间比较,度洛西汀组 PCS 评分明显优于非药物治疗组(P<0.05),而两组间 MCS 评分无显著差异(P>0.05)。此外,度洛西汀组在 1 周、2 周、1 个月、3 个月和 6 个月时的 EQ-5D 评分明显优于非药物治疗组(均 P<0.05)。

结论

与颈椎后路减压术后常规非药物治疗相比,口服度洛西汀可获得更好的短期疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/731d/10339503/1afe58eed17e/13018_2023_3970_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验